Travere therapeutics and csl vifor announce standard eu approval of filspari® (sparsentan) for iga nephropathy

San diego & st. gallen, switzerland--(business wire)---- $tvtx--travere therapeutics, inc., (nasdaq: tvtx) and csl vifor are pleased to announce that the european commission has approved the conversion of the conditional marketing approval (cma) into a standard marketing authorization (ma) for filspari for the treatment of adults with primary iga nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). standard ma is granted for all member states of the euro.
TVTX Ratings Summary
TVTX Quant Ranking